- Two cancer drugmaker rivals presented data on Monday about how combinations of their drugs, which harness the body's immune system to treat cancer, worked in treating a common form of lung cancer compared to traditional chemotherapy.
- Merck showed that its drug Keytruda in combination with chemotherapy cut the risk of death in lung cancer patients in half.
ADVERTISEMENT
2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner (MRK, BMY)
The markets picked Merck as the winner based on its data lung cancer. Merck's stock was up about 3% on Monday while BMS was down about 5%.
ADVERTISEMENT
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
Trends in online casino gaming in New Zealand
10 African countries with the highest number of migrants
PHOTOS: Inside the hostel in Rwanda set to house migrants from the UK in July
10 African countries with the weakest governments
Zap unveils Africa's first non-custodial exchange
The future of healthcare on display: Day 1 of Medlab West Africa wraps up
Nigeria suspends a Chinese business over discrimination charges
10 African countries with the greatest soft power influence over the world in 2024